Ticker

- BEACON2 is a landmark European multi-arm, multi-stage Phase 1/2 platform trial conducted and sponsored by the Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham  - Elraglusib will be assessed in combination with dinutuximab beta plus chemotherapy in patients with relapsed and refractory neuroblastoma - Complete response in neuroblastoma patient achieved in Phase 1 study of elraglusib in…

- Patients with KRAS wild-type (WT) genomics achieved significant improvement in median overall survival (mOS) when treated with elraglusib plus gemcitabine/Abraxane (GnP) versus GnP alone - Patients with P53WT genomics receiving elraglusib plus GnP showed a near doubling of mOS versus GnP alone - Patients receiving elraglusib plus FOLFIRINOX demonstrated deep and sustained clinical responses and increased mOS…

Elraglusib oral tablet formulation to drive next-phase clinical development and broader clinical use FDA cleared IND for Phase 1/2 study of oral elraglusib in advanced cancer patients, with focus on metastatic melanoma, NSCLC, colorectal, and pancreatic cancers with initiation planned for 2H 2026 Elraglusib plus RAS inhibitor preclinical results expected in mid-2026 Industry veteran Martin Huber, MD, joins Board of…

Some of Wall Street's biggest upside calls are not sitting in the mega-cap names. They are hiding in small, volatile stocks with thin balance sheets, limited operating history and one big event ahead.

Martin Huber, MD brings deep expertise in oncology drug development, regulatory strategy, and commercialization of novel therapies Martin Huber, MD brings deep expertise in oncology drug development, regulatory strategy, and commercialization of novel therapies